tradingkey.logo
搜尋

AIM ImmunoTech Inc

AIM
添加自選
0.257USD
+0.022+9.45%
收盤 07-31 16:00美東報價延遲15分鐘
2.12M總市值
虧損本益比TTM

關於 AIM ImmunoTech Inc 公司

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

AIM ImmunoTech Inc簡介

公司代碼AIM
公司名稱AIM ImmunoTech Inc
上市日期Jul 12, 1996
CEOEquels (Thomas K)
員工數量21
證券類型Ordinary Share
年結日Jul 12
公司地址2117 Sw Highway 484
城市OCALA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編32801
電話13524487797
網址https://aimimmuno.com/
公司代碼AIM
上市日期Jul 12, 1996
CEOEquels (Thomas K)

AIM ImmunoTech Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--

常見問題

AIM ImmunoTech Inc的前五大股東是誰?

AIM ImmunoTech Inc的前五大股東如下:Mr. Thomas K. Equels, Esq., J.D.

有多少機構持有AIM ImmunoTech Inc(AIM)的股份?

截至2026Q1,共有57家機構持有AIM ImmunoTech Inc的股份,合計持有的股份價值約為105.74K,占公司總股份的1.30% 。與2025Q4相比,機構持股有所增加,增幅為-74291.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有